Skip to main content
Premium Trial:

Request an Annual Quote

New Media for the New Biology

Premium

A new magazine? Why, in this Age of the Internet, would anyone do anything so retrograde as to start a new magazine? And about biology? And technology? Or technology and biology? What’s up with that?

Simply put, we think magazines are terrific -and we think that a great subject for one is the technology-led culture change in life sciences research. Call it what you will -industrial biology, systems biology, high-throughput this or large-scale that -there is no question that big change is afoot and that in coming years everyone in life sciences research will be affected.

Genome Technology is dedicated to documenting and illuminating that change for the people who are living through it and living in it.

Still, just because we are fond of dead-tree media like magazines doesn’t mean we disdain the Web. Not for nothing is our parent company called GenomeWeb. We happen to think that paper is good for some things and the Web is good for other things and that we are clever enough to combine them in a way that you will find useful. First read this magazine and then visit www.genomeweb.com. You’ll get the idea.

We are not here to out-science Science or to out-nature Nature. Our aim is to give you something to read that will help you to navigate and enjoy what we are calling the new biology.

In Genome Technology you will read about people and careers and problems and solutions and money and technology and trends and hype. And we hope that you find our approach clear and fair and fun.

So, on to the thank-yous. Thanks to our editorial team of journalists, photographers, and artists for delivering fabulous content. Thanks to our charter advertisers for seeing the wisdom of our approach. Thanks to our investors for continuing to believe in the magic of the printed page. And thanks especially to the visionary scientists, engineers, software gurus, entrepreneurs, and financiers who are creating the new biology, thereby giving us something to write about.

Let us know what you think of the inaugural issue. Send snail mail to Editor, Genome Technology,
125 Maiden Lane, Second Floor, New York, NY 10038
or e-mail to [email protected]

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.